Dendritic keratopathy associated with beta-blocker eyedrops.
Four patients with chronic open-angle glaucoma developed a dendriform corneal epithelial lesion. Two were associated with the use of topical betaxolol for 2 months and 6 weeks, and two were related to topical levobunolol. Resolution occurred within 2 weeks of discontinuation of the beta-blocker eyedrop. The distinctive pattern of dendritic epithelial keratopathy associated with these topical medications may be due to epithelial toxicity with subsequent regeneration.
Wilhelmus
K R
KR
Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX.
McCulloch
R R
RR
Gross
R L
RL
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D015784:Betaxolol / Q000009:adverse effects / Q000627:therapeutic use; D002908:Chronic Disease; D003316:Corneal Diseases / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D007635:Keratitis, Dendritic / Q000139:chemically induced*; D002040:Levobunolol / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D000317:Adrenergic alpha-Antagonists; D002040:Levobunolol; D015784:Betaxolol